251 related articles for article (PubMed ID: 21178714)
1. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.
Shiao TH; Chang YL; Yu CJ; Chang YC; Hsu YC; Chang SH; Shih JY; Yang PC
J Thorac Oncol; 2011 Jan; 6(1):195-8. PubMed ID: 21178714
[TBL] [Abstract][Full Text] [Related]
2. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
[TBL] [Abstract][Full Text] [Related]
3. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
5. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Park JH; Kim TM; Keam B; Jeon YK; Lee SH; Kim DW; Chung DH; Kim YT; Kim YW; Heo DS
Clin Lung Cancer; 2013 Jul; 14(4):383-9. PubMed ID: 23313171
[TBL] [Abstract][Full Text] [Related]
6. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
[TBL] [Abstract][Full Text] [Related]
7. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
[TBL] [Abstract][Full Text] [Related]
8. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
[TBL] [Abstract][Full Text] [Related]
9. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
Han HS; Lim SN; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Son SM; Choi SY; Lee HC; Lee OJ
J Thorac Oncol; 2012 Feb; 7(2):355-64. PubMed ID: 22157369
[TBL] [Abstract][Full Text] [Related]
10. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung.
Fukui T; Tsuta K; Furuta K; Watanabe S; Asamura H; Ohe Y; Maeshima AM; Shibata T; Masuda N; Matsuno Y
Cancer Sci; 2007 Nov; 98(11):1714-9. PubMed ID: 17784875
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
13. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
Chang YL; Wu CT; Shih JY; Lee YC
Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
[TBL] [Abstract][Full Text] [Related]
14. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
[TBL] [Abstract][Full Text] [Related]
15. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
16. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T
J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
[TBL] [Abstract][Full Text] [Related]
18. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
19. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
[TBL] [Abstract][Full Text] [Related]
20. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
